Keryx Biopharmaceuticals Inc

Keryx Biopharmaceuticals — Q3 2017 Earnings Presentation

28 slides from Keryx Biopharmaceuticals's earnings presentation, Nov 7, 2017

  1. Slide 1: U.S. FDA approval of Additional Indication for AURYXIA (ferric citrate) Tablets

    U.S. FDA approval of Additional Indication for AURYXIA® (ferric citrate) TABLETS Keryx Biopharmaceuticals, Inc 11/7/2017 www.keryx.com Exhibit 99.2

  2. Slide 2: Agenda

    Agenda Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Topic Speakers Welcome Amy Sullivan, SVP, Corporate Affairs Today’s Announcements & Importance of Auryxia® Greg Madison, President & CEO 3Q 2017 Results Scott Holmes, CFO Auryxia’s Broad Label John Neylan, M.D., Chief Medical Officer Commerci

  3. Slide 3: Forward-Looking Statements

    Forward-Looking Statements Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development of Auryxia may be forward-looking statements that involve a number of risks and unce

  4. Slide 4: Today's Announcements

    Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Today’s Announcements Greg Madison Chief Executive Officer

  5. Slide 5: Today's Announcements: Building a leading kidney care company

    Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Today’s Announcements Building a leading kidney care company

  6. Slide 6: 3Q 2017 Financial Results

    Copyright © 2017 by Keryx Biopharmaceuticals, Inc. 3Q 2017 Financial Results Scott Holmes Chief Financial Officer

  7. Slide 7: 3Q 2017 Auryxia Prescription Demand

    3Q 2017 Auryxia Prescription Demand Copyright © 2017 by Keryx Biopharmaceuticals, Inc. IMS / Specialty mix 3Q 2017: 55% / 45% * Impacted by overall mix of business between Medicare Part D, Commercial and Government Sources: IMS, Davita Rx, Fresenius Rx and Keryx data on file. Gross-to-net: 56%* +18%

  8. Slide 8: Selected Financial Results

    Selected Financial Results Copyright © 2017 by Keryx Biopharmaceuticals, Inc. ($ in millions) Three Months Ended Sept. 30, 2017 (unaudited) Three Months Ended Sept. 30, 2016 (unaudited) Nine Months Ended Sept. 30, 2017 (unaudited) Nine Months Ended Sept. 30, 2016 (unaudited) Net U.S. Auryxia Product

  9. Slide 9: Importance of Auryxia

    Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Importance of Auryxia® Greg Madison Chief Executive Officer

  10. Slide 10: Auryxia (ferric citrate) Tablets: New Indication

    Auryxia® (ferric citrate) Tablets Copyright © 2017 by Keryx Biopharmaceuticals, Inc. New Indication: treatment of iron deficiency anemia in adults with chronic kidney disease (CKD), not on dialysis Broad label supports use of Auryxia as a first-line treatment option Auryxia’s expanded indication now

  11. Slide 11: Overview of Iron Deficiency Anemia in Chronic Kidney Disease

    Overview of Iron Deficiency Anemia in Chronic Kidney Disease Copyright © 2017 by Keryx Biopharmaceuticals, Inc. One in seven people in the US has chronic kidney disease (CKD), more than half of them estimated to be iron deficient Occurs when the body does not have enough iron to produce sufficient n

  12. Slide 12: Auryxia's Profile

    Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Auryxia’s Profile John Neylan, M.D. Chief Medical Officer

  13. Slide 13: High Levels of Hepcidin Impair GI Absorption of Iron

    Copyright © 2017 by Keryx Biopharmaceuticals, Inc. High Levels of Hepcidin Impair GI Absorption of Iron Sources: (7) Babitt JL. J Am Soc Nephrol. 2012;23:1631-1634. (8) Goodnough LT, et al. Blood. 2010;116:4754-4761. (13) National Institute of Diabetes and Digestive and Kidney Diseases. https://www.

  14. Slide 14: Auryxia (ferric citrate) Tablets: Broad Label

    Copyright © 2017 by Keryx Biopharmaceuticals, Inc. INDICATIONS AND USAGE Auryxia is indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis Auryxia is indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney di

  15. Slide 15: Statistically Significant, Rapid Improvement in Hemoglobin

    Statistically Significant, Rapid Improvement in Hemoglobin Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Phase 3 Design: 16-week randomized, double-blind, placebo-controlled study, followed by an 8-week open-label safety extension phase Ferric citrate or matching placebo initiated at 3 tablets/

  16. Slide 16: Auryxia Safety Profile

    Auryxia® Safety Profile Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Source: Fishbane, JASN 2017 Pivotal Phase 3 study: Auryxia was well tolerated Majority of adverse events were mild to moderate Gastrointestinal adverse reactions were the most common reason for discontinuing Auryxia Incidence

  17. Slide 17: ASN 2017: Keryx Accepted Abstracts

    ASN 2017: Keryx Accepted Abstracts Oral: Ferric Citrate Reduces FGF23 in Patients With Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Iron Deficiency Anemia (IDA) Irrespective of the Change in Serum Phosphate (P) Authors: Block GA, Pergola PE, Uhlig K, Neylan JF, Fishbane S, Chertow GM

  18. Slide 18: Thank You!

    THANK YOU! Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Source: Fishbane, JASN 2017 To the… Patients who participated in our clinical trials and their families Physicians Nurses Study coordinators U.S. Food & Drug Administration

  19. Slide 19: Commercial Strategy and Launch Focus

    Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Commercial Strategy and Launch Focus Doug Jermasek VP, Marketing and Strategy

  20. Slide 20: Promotional Marketing Campaign

    Promotional Marketing Campaign Copyright © 2017 by Keryx Biopharmaceuticals, Inc.

  21. Slide 21: Adults in the U.S. with Iron Deficiency Anemia and Chronic Kidney Disease

    Adults in the U.S. with Iron Deficiency Anemia and Chronic Kidney Disease Copyright © 2017 by Keryx Biopharmaceuticals, Inc. 30 MILLION U.S. ADULTS WITH CKD ~650K treated for Iron Deficiency Anemia ~350K on phosphate binders ~ 450K on dialysis 250K-400K Market development opportunity ~ 1.7MM adults

  22. Slide 22: Key Launch Objectives

    Key Launch Objectives Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Drive rapid awareness of new indication in iron deficiency anemia Differentiate Auryxia from existing treatment options Communicate favorable reimbursement access to Auryxia

  23. Slide 23: New Indication Provides Significant Commercial Leverage

    New Indication Provides Significant Commercial Leverage Copyright © 2017 by Keryx Biopharmaceuticals, Inc. 95 Renal Sales Specialists Current Physician Targets Care for 450,000 dialysis patients Care for 1.7 million pre-dialysis CKD patients Auryxia Conversations Auryxia Covered on all major Medicar

  24. Slide 24: Closing Remarks

    Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Closing Remarks Greg Madison Chief Executive Officer Keryx Biopharmaceuticals, Inc

  25. Slide 25: Key Takeaways

    Key Takeaways Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Remainder of 2017 focused on: Educating physicians about Auryxia Field team training Continue to drive adoption in dialysis for Auryxia’s use as a phosphate binder Building foundation to achieve vision of multi-product kidney care comp

  26. Slide 26: Strong Foundation to Build a Leading Kidney Care Company

    Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Phosphate Management Anemia Management Strong Foundation to Build a Leading Kidney Care Company THANK YOU!

  27. Slide 27: Strong Foundation to Build a Leading Kidney Care Company

    Copyright © 2017 by Keryx Biopharmaceuticals, Inc. Phosphate Management Anemia Management Strong Foundation to Build a Leading Kidney Care Company

  28. Slide 28: U.S. FDA approval of Additional Indication for AURYXIA (ferric citrate) Tablets

    U.S. FDA approval of Additional Indication for AURYXIA® (ferric citrate) TABLETS Keryx Biopharmaceuticals, Inc 11/7/2017 www.keryx.com

Keryx Biopharmaceuticals — Q3 2017 Earnings Presentation on 6ix